From Grafa:
Paradigm Biopharmaceuticals is currently conducting a global, Phase 3 clinical trial for its iPPS treatment for osteoarthritis (OA).In this interview, Paradigm Biopharmaceuticals Managing Director Paul Rennie discusses the potential for the company’s breakthrough treatment to break into the $8.28 billion global market for osteoarthritis therapeutics. Paradigm has cashed up, having raised $30.1 million in October last year to develop its iPPS treatment for the disease.
https://grafa.com/news/paradigm-biopharmaceuticals--asx-par--conducting-phase-3-osteoarthritis-trial-179958
From Grafa:Paradigm Biopharmaceuticals is currently conducting a...
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $85.7M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 26.0¢ | 23.5¢ | $164.7K | 667.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 265510 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 49891 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |